ESSEX BIO-TECH (01061) announced its interim results for the six months ended June 30, 2025. The company reported revenue of HK$877 million, representing a year-on-year increase of 5.79%. Profit for the period reached HK$163 million, up 3.79% compared to the same period last year. Basic earnings per share stood at HK$0.2882. The company proposed an interim dividend of HK$0.07 per share.